CSIMarket


Iterum Therapeutics Plc  (ITRM)
Other Ticker:  
 


 

Iterum Therapeutics Plc

ITRM's Financial Statements and Analysis



Iterum Therapeutics Plc narrowed third quarter of 2023 net loss per share of $-0.30 compare to net loss per share of $-2.38 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.95 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -0.3 $  13 Mill
$+2.08     $+18M    



Iterum Therapeutics Plc's Revenue rose by -373.05 % in third quarter of 2023 (Sep 30 2023) year on year, to $13 million and advanced by sequentially.


Iterum Therapeutics Plc is

More on ITRM's Income Statement



Iterum Therapeutics Plc's in thethird quarter of 2023 recorded net loss of $-3.877 million, an improvement compare to net loss of $-29.109 million in III. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-12.243 million realized in previous quarter.

More on ITRM's Growth

Iterum Therapeutics Plc Inventories
In Sep 30 2023 company's net cash and cash equivalents decreased by $-9 million


Iterum Therapeutics Plc does not pay out common stock dividend.

In trailing twelve-month period Iterum Therapeutics Plc payed $ -2.36 cash per share, on a free-cash flow basis .

Book value fell by -52.21 % sequentially to $0.26 per share, -13.98% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.23 per share from $ 0.48.

Company issued 0.10 million shares or 0.75 % in Sep 30 2023.
Interest Coverage Ratio was 3.84. Debt Coverage Ratio was 1.35.

More on ITRM's Dividends

 Market Capitalization (Millions) 20
 Shares Outstanding (Millions) 13
 Total Debt (Millions $) 12
 Revenue (TTM) (Millions $) 14
 Net Income (TTM) (Millions $) -31
 Cash Flow (TTM) (Millions $) -16
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Iterum Therapeutics Plc does not pay out common stock dividend.

In trailing twelve-month period Iterum Therapeutics Plc had negative $ -2.36 cash flow per share, on a free-cash flow basis .

Book value fell by -52.21 % sequentially to $0.26 per share, -13.98% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.23 per share from $ 0.48.

Company issued 0.10 million shares or 0.75 % in Sep 30 2023.
Interest Coverage Ratio was 3.84. Debt Coverage Ratio was 1.35.

More on ITRM's Balance Sheets

 Market Capitalization (Millions) 20
 Shares Outstanding (Millions) 13
 Total Debt (Millions $) 12
 Revenue (TTM) (Millions $) 14
 Net Income (TTM) (Millions $) -31
 Cash Flow (TTM) (Millions $) -16
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Iterum Therapeutics Plc Earnings

Iterum Therapeutics Plc Reports Impressive Financial Performance in Q3 2023, Showing Promising Progress towards Profitability2.

Iterum Therapeutics Plc Makes Progress in Q3 2023, Investors Optimistic for Future
Iterum Therapeutics Plc, a major player in the field of pharmaceutical preparations, has shown impressive improvements in its financial performance during the third quarter of 2023. The company reported a decrease in loss per share from $-2.38 to $-0.30, compared to the previous year's reporting season. Additionally, revenue turned positive and income per share improved significantly. These positive indicators have caught the attention of investors, who eagerly await the company's upcoming financial earnings report on March 15, 2024.
During the third quarter of 2023, Iterum Therapeutics Plc reported a net deficit of $-...

Shedding Light on Iterum Therapeutics Plc: Unearthing Surprising Financial Results for Q2 2023

Iterum Therapeutics Plc, a pharmaceutical company specializing in the development of innovative therapies, recently announced its financial results for the second quarter of 2023. Despite the company reporting a deficit per share of $-0.95, an increase from $-0.04 per share in the same quarter last year, it is essential to consider multiple factors and perspectives to gain a comprehensive understanding of the situation.
Firstly, it is crucial to note that the deficit per share in the second quarter of 2023 is higher than the previous quarter, where the company reported a deficit per share of $-0.78. This indicates a declining financial performance within a relatively short time frame. However, it is nece...

Iterum Therapeutics Plc's Grave Financial Struggles Highlighted with Astounding $51 Million Loss

Iterum Therapeutics Plc, a pharmaceutical company that specializes in developing and commercializing anti-infectives, recorded a significant net loss of $-51 million during the 12 months ending in the first quarter of 2023. This resulted in a negative return on assets (ROA) of -74.39%, significantly lower than the industry average. However, it is important to note that the healthcare sector saw the participation of 646 other companies, which recorded a higher return on assets.
Despite the negative ROA, Iterum Therapeutics Plc's overall ranking has improved, with the company rising from the 4733rd rank in the fourth quarter of 2022 ...


Date modified: 2023-11-16T19:17:19+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com